PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D	21	JUL 2005	1
TAMBO		PC	T

Applicant's or agent's file reference		FOR FURTHER ACTI	ON	See Form PCT/IPEA/416				
9635-039-228								
International application No.		International filing date (da	y/month/year)	Priority date (day/month/year)				
PCT/US04/09622		29 March 2004 (29.03.2004		28 March 2003 (28.03.2003)				
International Patent Classification (IPC) or national classification and IPC								
IPC(7): C12P 21/08; C07K 16/28 and US C1.: 530/387.3, 388.22								
Applicant								
HIMAWAN, JEFF								
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.								
2. This R	EPORT consists of	f a total of 3 sheets, inclu	ding this cover sheet	i.				
3. This re	. This report is also accompanied by ANNEXES, comprising:							
a. 🔲	a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:							
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.							
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))								
4. This re	port contains indic	cations relating to the follow	ving items:					
\boxtimes	Box No. I	Basis of the report						
	Box No. II	Priority						
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			velty, inventive step and industrial				
	Box No. IV	ack of unity of invention						
\boxtimes	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement							
	Box No. VI	Certain documents cited						
	Box No. VII	Certain defects in the interr	ational application					
	Box No. VIII	Certain observations on the	international applic	ation				
Date of submission of the demand			Date of completion	n of this report				
26 October 2004 (26.10.2004) 14 July 2005 (14.07.2005)								
Name and mailing address of the IPEA/US Authorized officer ()								
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450								
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Telephone No. (571) 272-1600								
Pacsimile No. (703) 305-3230								

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

1	International application No.
	PCT/US04/09622

Box No. I Basis of the report					
 With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item. 					
This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:					
international search (under Rules 12.3 and 23.1(b))					
publication of the international application (under Rule 12.4)					
international preliminary examination (under Rules 55.2 and/or 55.3)					
2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
the international application as originally filed/furnished					
the description:					
pages 1-57 as originally filed/furnished					
pages* NONE received by this Authority on					
the claims:					
pages 58-70 as originally filed/furnished pages* NONE as amended (together with any statement) under Article 19					
pages* NONE received by this Authority on					
pages* NONE received by this Authority on					
the drawings: pages 1-16 as originally filed/furnished					
pages* NONE received by this Authority on					
pages* NONE received by this Authority on					
a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.					
3. The amendments have resulted in the cancellation of:					
the description, pages					
the claims, Nos					
the drawings, sheets/figs					
the sequence listing (specify):					
any table(s) related to the sequence listing (specify):					
4. This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).					
the description, pages					
the claims, Nos					
the drawings, sheets/figs					
the sequence listing (specify):					
any table(s) related to the sequence listing (specify):					
* If item 4 applies, some or all of those sheets may be marked "superseded."					
D. DOWNER 4/00 (Day Ma. D. (January 2004)					

Form PCT/IPEA/409 (Box No. I) (January 2004)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/09622

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
Statement N	ovelty (N)	Claims <u>1-63</u> Claims <u>NONE</u>	yes no
Ir	nventive Step (IS)	Claims 1-63 Claims NONE	YES NO
Ir	ndustrial Applicability (IA)	Claims <u>1-63</u> Claims <u>NONE</u>	yes no

2. Citations and Explanations (Rule 70.7)
Claims 1-63 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest E11 anti-CR1 antibodies of SEQ ID NO: 2 with the specifically claimed modifications for reducing immunogenicity of the antibody or use of modified antibody. Hogg et al. (of record) teaches the identification of the E11 anti-CR1 monoclonal antibody but does not teach or suggest modifications for reducing the immunogenicity of the monoclonal antibody.

Claims 1-63 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.